San Diego-based Gossamer Bio released long-awaited Phase 3 data today for its drug seralutinib, revealing a complex set of results that both challenged and encouraged researchers. The PROSERA study, which tested the inhaled medication in patients with pulmonary arterial hypertension (PAH), officiall y missed its primary goal by a narrow margin. However, the drug appeared to […] Gossamer Bio, Seralutinib Misses Tight Statistical Mark But Shows Heart In High-Risk Lung Disease Study ...read more read less